According to filings with the U.S. Securities and Exchange Commission, vTv Therapeutics is raising up to $50,961,457.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Steven Tuch played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About vTv Therapeutics
vTv is a clinical stage biotechnology company with a pipeline of drug candidates led by cadisegliatin (TTP399), a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients. vTv has a pipeline of clinical drug candidates developed using our innovative technology and led by our TTP399 program for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, renal disease, primary mitochondrial myopathy, and pancreatic cancer.

To learn more about vTv Therapeutics, visit http://www.vtvtherapeutics.com/

Contact:
Steven Tuch, Chief Financial Officer
336-841-0300
https://www.linkedin.com/in/steven-tuch-399bbb30/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.